Prognosis of Ocular Myasthenia Gravis: Retrospective Multicenter Analysis by Nagia, L et al.
Prognosis of Ocular Myasthenia Gravis
Retrospective Multicenter Analysis
Lina Nagia, DO,1 Joao Lemos, MD,2 Khawla Abusamra, MD,3 Wayne T. Cornblath, MD,4
Eric R. Eggenberger, DO, MSEpi5
Purpose: To calculate the rate and timing of conversion from ocular myasthenia gravis to generalized
myasthenia gravis.
Design: Retrospective multicenter analysis.
Subjects: Patients included in the study were diagnosed with ocular myasthenia gravis without the presence
of generalized disease at onset.
Methods: We conducted a retrospective multicenter analysis. We reviewed charts of 158 patients who met
diagnostic criteria for ocular myasthenia gravis. Patients were divided into 2 subgroups: an immunosuppressant
treatment group and a nonimmunosuppressant treatment group. Timing of conversion to generalized disease and
duration of follow-up also was evaluated. Additional data such as clinical symptoms at presentation, laboratory
test results, and chest imaging results also were recorded.
Main Outcome Measures: Conversion rates to generalized myasthenia at 2 years, effect of immunosup-
pression on conversion, and timing of conversion.
Results: The 158-patient cohort included 76 patients who received immunosuppressant therapy; the
remaining 82 patients did not. The overall conversion rate to generalized disease was 20.9%. At 2 years,
generalized myasthenia developed in 8 of 76 patients in the treated group and in 15 of 82 patients in the non-
immunotherapy group (odds ratio, 0.52; 95% conﬁdence interval, 0.20e1.32). Median time for conversion to
generalized disease was 20 months in the nonimmunosuppressant group and 24 months in the immunosup-
pressant group. Conversion occurred after 2 years of symptom onset in 30% of patients.
Conclusions: Conversion rates from ocular to generalized myasthenia gravis may be lower than previously
reported both in immunosuppressed and nonimmunosuppressed patients. A subset of patients may continue to
convert to generalized disease beyond 2 years from onset of symptoms, and close monitoring should be
continued. Ophthalmology 2015;122:1517-1521 ª 2015 by the American Academy of Ophthalmology.The pathophysiologic features of myasthenia gravis are
related to autoimmunity directed against the acetylcholine
receptor (AChR) of the neuromuscular junction, leading to
reduced acetylcholine binding to its receptors and striated
muscle weakness.1 The initial presentation is limited to
pure ocular symptoms (diplopia, ptosis, or both) in
approximately 50% to 60% of cases.2 Conversion rates
from ocular myasthenia gravis (OMG) to generalized
myasthenia gravis (GMG) traditionally are accepted to
be in the range of 50% to 65%.2e4 Prior reports indicate
that more than 90% of OMG patients converting to GMG
do so within 2 years.2,3,5 More recently, Sommer et al6
and Kupersmith et al5 showed conversion rates of 31%
and 36%, respectively, with rates as low as a 7%5 in the
subgroup of patients receiving immunosuppressive
therapy followed up for a mean of 8.3 and 3.6 years. In
addition, age, AChR antibody titers, and thymoma have
been postulated to affect conversion rates.2,5,6 We
sought to calculate the rate and timing of conversion and
to report on factors inﬂuencing conversion for our patient
cohort. 2015 by the American Academy of Ophthalmology
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We conducted a retrospective chart review of patients with OMG
who sought treatment at the neuro-ophthalmology clinics of 6
practicing physicians at Michigan State University or the University
of Michigan between 1993 and 2012. Approval for the study was
granted by each institution’s institutional review board before
accessing patient medical records and abstracting data to an ano-
nymized OMG database. Inclusion criteria consisted of age 18 years
or older, 2 years or more of follow-up after diagnosis, and fulﬁlling
our deﬁnition of OMG: the presence of diplopia, ptosis, or both
(according to the criteria of Osserman and Genkins7) and at least 1 of
the following: (1) positive acetylcholine receptor antibody (AChR
Ab) titer, (2) signiﬁcant jitter in single-ﬁber electromyography
(sfEMG), or (3) unequivocal clinical response to edrophonium
chloride (Tensilon test) or pyridostigmine. Exclusion criteria
included history of prior or active thyroid eye disease, prior stra-
bismus surgery, or GMG occurrence either at the onset of symptoms
or within the ﬁrst month of OMG. Generalized myasthenia gravis
was deﬁned as the development of symptoms or clinical ﬁndings
such as dysphagia, dysarthria, dyspnea, or weakness of the face
(except for orbicularis oculi), jaw, neck, or extremities. After OMG
diagnosis, patients received acetylcholinesterase inhibitor treatment1517http://dx.doi.org/10.1016/j.ophtha.2015.03.010
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Table 1. Background Features of Patients with Ocular Myasthenia Gravis
All Patients (n [ 158)
Nonimmunosuppressant
Group (n [ 82)
Immunosuppressant
Group (n [ 76) P Value
Gender, no. (%) 0.49
Male 106 (67.1) 53 (64.6) 53 (69.7)
Female 52 (32.9) 29 (35.4) 23 (30.3)
Median age (IQR), yrs 61.5 (21) 61.5 (22) 61.5 (21) 0.57
Symptoms, no. (%)
Diplopia 143 (90.5) 70 (85.4) 73 (96.1) 0.02
Ptosis 104 (65.8) 54 (65.9) 50 (65.8) 0.99
Both 89 (56) 41 (50) 48 (63.2)
AChR Ab positive titer results, no. (%) 113/157 (72) 56/82 (68.3) 57/75 (76) 0.283
sfEMG pathologic response, no. (%) 51/59 (86.4) 24/29 (82.8) 27/30 (90) 0.47
Positive clinical results, no. (%)
Tensilon test 21/21 (100) 8/8 (100) 13/13 (100) d
Pyridostigmine 15/15 (100) 9/9 (100) 6/6 (100) d
Presence of thymoma, no. (%) 8 (5.1) 6 (7.3) 2 (2.6) 0.27
Median follow-up (IQR), mos 60.5 (82) 64.5 (85.5) 57.5 (57.7) 0.34
AChR Ab ¼ acetylcholine receptor antibody; IQR ¼ interquartile range; sfEMG ¼ single-ﬁber electromyography.
Ophthalmology Volume 122, Number 7, July 2015(pyridostigmine), immunosuppressive treatment (corticosteroids,
azathioprine, mycophenolate mofetil, methotrexate, cyclosporine,
plasmapheresis, or intravenous immunoglobulin [IVIG]), or no
treatment at the individualized discretion of the treating physician.
The following variables at clinical presentation were evaluated: age
recorded in years, gender, clinical symptoms (diplopia, ptosis, or
both), AChR antibody titer status, sfEMG response, clinical
response to Tensilon test and pyridostigmine, presence of thymus
pathologic features, and type of therapy. We evaluated duration of
follow-up in months, conversion status (development of GMG),
time to GMG conversion (calculated from time of symptom onset),
and treatment method (immunosuppressant versus non-
immunosuppressant therapy). Results of chest imaging, computed
tomography, or magnetic resonance imaging were recorded.
For the statistical analysis, we used the chi-square square test
(or Fisher exact test) and ManneWhitney U test when comparing
baseline variables between immunosuppressant and non-
immunosuppressant treatment groups. The odds ratio (OR) of
GMG developing at 2 years of follow-up was calculated for the
different variables and was expressed with 95% conﬁdence in-
tervals (CIs). Univariate and multivariate logistic regression was
performed to study the association between baseline variables and
the development of conversion to GMG at 2 years. Kaplan-Meyer
estimation was performed to evaluate the inﬂuence of treatment
method, the presence of thymoma, and AChR antibody titer status
on the time to conversion to GMG during the follow-up period.
Univariate and multivariate proportional hazards regression ana-
lyses were used to determine the associations between baseline
variables and the risk of conversion during the follow-up period. A
P value less than 0.05 was considered signiﬁcant. All data analyses
were performed using SPSS Statistics for Windows version 20.0
(IBM Corp, Armonk, NY).Results
One hundred ﬁfty-eight patients with ocular myasthenia gravis
fulﬁlling our inclusion or exclusion criteria were identiﬁed from our
retrospective chart review. Of the 158 included, 106 (67.1%) were
men and 52 (32.9%) were women, with a median age at onset of
symptoms of 61.5 years (interquartile range, 21 years; range, 18e85
years) and a median follow-up period of 60.5 months (interquartile1518
Downloaded for Anonymous User (n/a) at CONSORTIUM OF PORTUGAL-Centro Hospi
For personal use only. No other uses without permission.range, 82 months; range, 24e300 months). Of the 158 patients,
diplopia alone was present in 54 patients (34%), ptosis alone in 15
patients (10%), and both symptoms coexisting in 89 patients (56%).
Of the 158-subject cohort, testing included AChR antibody titer
alone (77 patients); AChR antibody titer and sfEMG (59 patients);
AChR antibody titer and edrophonium (Tensilon; 17 patients);
AChR antibody, sfEMG and Tensilon test (4 patients); and only 1
patient classiﬁed by clinical response to pyridostigmine (no AChR
antibody titer, sfEMG, or Tensilon test). Diagnosis of OMG was
based on symptoms in combination with: (1) positive acetylcholine
receptor antibody titer results in 113 (72%) of 157 patients tested,
(2) abnormal sfEMG results in 51 (86.4%) of 59 patients tested, (3)
clinical response to Tensilon test in all 21 patients tested, and (4)
clinical response to pyridostigmine in all 9 patients tested. Thy-
moma was diagnosed by chest imaging in 8 (5.1%) of 158 patients,
and thymectomy was performed in all 8; thymic hyperplasia was
noted in 1 patient (0.6%). Patients were grouped further by treat-
ment category: immunosuppressant treatment (IT) group or no
immunosuppressant treatment (NIT) group (Table 1). The IT group
contained 76 (48.1%) patients: corticosteroids, n ¼ 50;
mycophenolate, n ¼ 14; azathioprine, n ¼ 1; methotrexate, n ¼ 1;
corticosteroids in combination with mycophenolate, n ¼ 5;
corticosteroids in combination with mycophenolate and IVIG,
n ¼ 2; corticosteroids in combination with IVIG and
plasmapheresis, n ¼ 1; corticosteroids in combination with
methotrexate, n ¼ 1; and azathioprine in combination with
cyclosporine, n ¼ 1. The NIT group consisted of 82 (51.9%)
patients: pyridostigmine, n ¼ 77; prismatic lens n ¼ 1; and no
treatment, n ¼ 4. Among the participating physicians,
pyridostigmine was the ﬁrst therapeutic choice in all patients,
whereas prednisone, other immunosuppressive agents, or both were
considered if lack of efﬁcacy or side effects occurred. The median
time to starting immunosuppressive therapy was 6 months.
Except for the incidence of diplopia, which was more frequent
in the NIT group (P ¼ 0.02, chi-square test), there was no sta-
tistical difference in baseline characteristics between the 2 sub-
groups, including gender, age at the onset of symptoms, ptosis
incidence, AChR abnormal titer results, abnormal sfEMG results,
presence of thymoma, and follow-up duration (Table 1).
Of the 158 patients with OMG, 33 (20.9%) converted to GMG.
Among these, 4 (12.1%) patients did so within the ﬁrst 6 months,
another 6 (18.1%; cumulative, 30.2%) within 1 year, 13 (39.3%;talar e Universitário de Coimbra from ClinicalKey.com by Elsevier on June 27, 2018.
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Table 2. Risk for Conversion to Generalized Myasthenia Gravis
by 2 Years
Risk Factor
Conversion to
Generalized
Myasthenia Gravis
by 2 Years,
No. (%)
P
Value
Odds Ratio
(95% Conﬁdence
Interval)
Gender 0.83
Male 15/106 (14.2) d
Female 44/52 (15.4) 1.10 (0.43e2.79)
Age (yrs) 0.22
50 8/39 (20.5) d
>50 15/119 (12.6) 0.55 (0.21e1.44)
AChR Ab titer results 0.08
Negative 3/44 (6.8) d
Positive 20/113 (17.7) 2.93 (0.82e10.44)
sfEMG response 0.29
Normal 2/8 (25) d
Abnormal 6/51 (11.8) 0.40 (0.06e2.45)
Thymoma 0.09
Not present 20/150 (13.3) d
Present 3/8 (37.5) 3.90 (0.86e17.59)
Treatment 0.16
NIT 15/82 (18.3) d
IT 8/76 (10.5) 0.52 (0.20e1.32)
AChR Ab ¼ acetylcholine receptor antibody; IT ¼ immunosuppressant
therapy; NIT ¼ no immunosuppressant therapy; sfEMG ¼ single-ﬁber
electromyography.
Figure 1. Kaplan-Meier curve of the cumulative conversion to generalized
myasthenia gravis (GMG) after onset of symptoms in immunosuppressant-
treated patients and nonimmunosuppressant-treated patients.
Figure 2. Kaplan-Meier curve of the cumulative conversion to generalized
myasthenia gravis (GMG) after onset of symptoms in patients with and
without thymoma.
Nagia et al  Prognosis of Ocular Myasthenia Graviscumulative, 69.3%) during the second year, and the remaining 10
(30.3%) patients after 2 years. The median time to GMG conver-
sion was 20 months (interquartile range, 36 months; range, 2e156
months). We did not observe a signiﬁcant association between the
risk for conversion to GMG and demographic or baseline factors,
including gender, age younger than 50 years, and abnormal sfEMG
results (Table 2). Patients with thymoma showed a trend for
increased risk of conversion to GMG (P ¼ 0.09, Fisher exact
test; the OR for converting to GMG was 3.90 [95% CI,
0.86e17.59] compared with patients without thymoma). Patients
with positive AChR antibody titer results showed a similar trend
(P ¼ 0.08, chi-square test; OR, 2.93; 95% CI, 0.82e10.44). Pa-
tients taking immunosuppressants evidenced the opposite trend
(P ¼ 0.16, chi-square test). In the ﬁrst 2 years, although 15 (18.3%)
of 82 patients in the NIT group converted to GMG, 8 (10.5%) of 76
patients in the IT group demonstrated GMG, corresponding to an
OR of 0.52 (95% CI, 0.20e1.32).
Using a univariate logistic regression model to calculate the OR
of GMG developing by 2 years according to gender, age, AChR
antibody titer status, presence of thymoma, or use of immuno-
suppressants did not indicate signiﬁcant effects. After controlling
for the other factors in a multivariate model, no variable reached a
signiﬁcant association with the outcome (AChR antibody titer: OR,
3.34; 95% CI, 0.87e12.83; P ¼ 0.79; presence of thymoma: OR,
2.59; 95% CI, 0.49e13.61; P ¼ 0.26; use of non-
immunosuppressants: OR, 0.53; 95% CI, 0.20e1.38; P ¼ 0.19).
The median time for conversion to GMG in the NIT group was
20 months (interquartile range [IQR], 17.2 months; range, 2e120
months), whereas in the IT group, it was 24 months (IR, 60
months; range, 3e156 months). In patients without thymoma, the
median time for conversion to GMG was 18 months (IR, 39
months; range, 2e156 months), compared with 24 months in pa-
tients with thymoma (range, 20e24 months). In patients with
negative AChR antibody titer results, the median time forDownloaded for Anonymous User (n/a) at CONSORTIUM OF PORTUGAL-Centro Hospi
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3e120 months), whereas in the positive AChR antibody titer re-
sults group, the median time for conversion to GMG was 20
months (IQR, 19 months; range, 2e156 months). The log-rank test
did not reveal a signiﬁcant difference in the rate of conversion to1519
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Figure 3. Kaplan-Meier curve of the cumulative conversion to generalized
myasthenia gravis (GMG) after onset of symptoms in patients with nega-
tive and positive acetylcholine receptor antibody (AChR Ab) titer results.
Ophthalmology Volume 122, Number 7, July 2015GMG between the 2 treatment groups (P ¼ 0.37), between patients
with and without thymoma (P ¼ 0.28), or between patients with
positive versus negative AChR antibody titer results (P ¼ 0.17;
Figs 1, 2, and 3).
Univariate Cox proportional hazards regression analyses revealed
that neither gender, actual age, presence of thymoma, AChR antibody
titer status, or use of immunosuppressants signiﬁcantly reduced the
risk of conversion to GMG (P¼ 0.61, P¼ 0.39, P¼ 0.29, P¼ 0.15,
and P ¼ 0.37, respectively). Age, presence of thymoma, AChR
antibody titer status, and use of immunosuppressants were not sig-
niﬁcant in the multivariate model, either.
Discussion
Our study, which included 158 patients with median follow-
up of 60.5 months, represents a large, long-term, collabo-
rative experience concerning conversion rates from OMG to
GMG. Sommer et al6 included 78 patients with mean
disease duration of 8.3 years (99 months), Hong et al8
presented 202 patients with a median follow-up period of
11.8 months, and Kupersmith et al5 had 147 patients with
mean follow-up of 3.6 years (43 months). With regard to
demographics, our population had a male prevalence at
67%, with a median age at symptom onset of 61.5 years;
comparatively, Sommer et al had a 51% male prevalence
with a mean age at onset of 50.6 years, and Kupersmith et al
had a 57% male prevalence with mean age at onset of 50
years. Eight patients (5.1%) in our OMG cohort harbored a
thymoma, similar to previous reported incidence rates
(0.7%5 and 2.2%9). Regarding clinical features at
presentation, 10% of our patients reported ptosis alone,
34% experienced only diplopia, and most, 56%, had both
symptoms. AChR antibody titer was performed in most of1520
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positive titer results. Previous studies have reported
seropositive titers in OMG patients at a range of 35% to
100%.5,6,8e10 Unlike the previous study by Kupersmith
et al,11 our IT and NIT subgroups had equal proportions of
AChR antibody positivity, eliminating this variable when
comparing conversion rates between the 2 groups.
Previous studies have shown overall conversion rates of
OMG to GMG of 50% to 64%.2,4,12,13 Our series of OMG
patients showed a much lower overall conversion rate of
20.9%, consistent with more recent retrospective studies
reporting overall conversion rates ranging from 23% to
31%,6,8,14,15 and this low conversion rate was observed in
subjects with or without immunosuppressant therapy. Prior
studies have emphasized the possible effect of immunotherapy
on conversion rates. Sommer et al6 reported conversion of
12% in treated and 64% in untreated patients, and
Kupersmith et al5 reported a 7% conversion rate in the
treated group versus 36% in patients not treated with
prednisone. Monsul et al16 reported conversion in 11% of
the treated group and 34% of the untreated group at 2 years.
Nonetheless, there are no randomized controlled studies to
test this hypothesis, and in our series, the IT group had a
10.5% conversion rate (n ¼ 76) compared with 18.3%
conversions in the NIT group (n ¼ 82; P ¼ 0.16) within the
ﬁrst 2 years; the conversion rate in our NIT subgroup was
notably lower than that reported previously in the
literature.2,4,12,13 Kaplan-Meier estimates comparing our IT
and NIT groups showed no difference in cumulative conver-
sion rates between the 2 groups in the ﬁrst 18 months, or
beyond 90 months from symptom onset.
No predictive factors for GMG conversion were found,
including gender, age, or AChR-positive titer status, either
in univariate and multivariate analysis. Interestingly, the
presence of thymoma and AChR-positive titer showed a
trend toward predicting conversion; however, this is small
subgroup analysis. Previous retrospective studies have
shown increased risk of conversion with AChR antibody
positivity5,8 and thymoma.8 In our series, although the
median age of our cohort was slightly older than that of
the cohorts of Sommer et al and Kupersmith et al, age did
not inﬂuence the outcome in the multivariate model.
Previous reports have shown a trend toward frequent
progression to the generalized form of myasthenia in older
patients17,18; however, that did not occur in our series.
Additionally, we point out that median age was balanced
between our IT and NIT groups, eliminating age bias in the
calculations of conversion rates.
Prior studies have noted that approximately 80% of pa-
tients converting to GMG will do so within the ﬁrst year, and
90% within 3 years.2,12,13 In contrast, our study showed 30%
of patients converting within 1 year, 70% within 2 years, and
30% converted only after 2 years from symptom onset.
Sommer et al6 also noted 50% of their converting patients did
so in the ﬁrst 2 years, and 75% did so within 4 years.
As with any retrospective chart review, this study has its
limitations in sample size, heterogeneity of treatment, and
nonstandardized evaluation criteria; however, this multi-
center experience involving several clinicians may better
mirror disease characteristics and behavior in general. Wetalar e Universitário de Coimbra from ClinicalKey.com by Elsevier on June 27, 2018.
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Nagia et al  Prognosis of Ocular Myasthenia Gravisbelieve the clinical implications of these results are signiﬁ-
cant in several ways. First, the overall conversion rate from
OMG to GMG is lower than previously reported, both in the
immunosuppressed and nonimmunosuppressed cohorts.
Second, caution should be taken in assuring patients that the
risk of conversion after 2 years is minimal, and we believe
that patients should continue to be monitored beyond the
ﬁrst 2 years. Additionally, trials evaluating immunosup-
pressant therapy for its effect on generalization need to take
into account planned follow-up beyond 2 years; such studies
also need to be powered for a lower generalization rate,
factors that challenge large-scale feasibility especially given
that many patients will receive immunosuppressant therapy
for symptom control regardless of possible effects on
generalization.
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